Dong Zheng,1 Tong Chen,2 Kaiyuan Yang,1 Guangrong Yin,1 Yang Chen,3 Jianchao Gui,4 Chao Xu,1 Songwei Lv5

1Department of Orthopedics, The Affiliated Changzhou No.2 People’s Hospital with Nanjing Medical University, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, People’s Republic of China; 2Department of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China; 3Changzhou Productivity Development Center, Changzhou, People’s Republic of China; 4Department of Sports Medicine and Joint Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, People’s Republic of China; 5School of Pharmacy, Changzhou University, Changzhou, People’s Republic of China

Correspondence: Chao Xu, Email [email protected]; Songwei Lv, Email [email protected]

View the original paper by Dr Zheng and colleagues

This is in response to the Letter to the Editor

Thank you for your letter and for the readers’ comments concerning our manuscript entitled “Microfluidic Synthesis of miR-200c-3p Lipid Nanoparticles: Targeting ZEB2 to Alleviate Chondrocyte Damage in Osteoarthritis”. These opinions have a certain guiding significance for our follow-up research.

Thank you for your interest in our research and your question regarding the lack of animal experiments in our studies. We want to clarify that we are conducting relevant animal experiments; however, due to the need for ethical approval and the duration of the experimental cycle, we do not yet have complete results. We look forward to sharing our findings with you as soon as they are available. The stability and potential side effects of nanomaterials pose significant challenges to the advancement of nanopharmaceutics. To address this issue, we have chosen liposome nanomaterials, which are widely used in clinical practice, to facilitate the process of clinical transformation. The pathological mechanisms of osteoarthritis are quite complex. This paper primarily focuses on the inflammatory response triggered by lipopolysaccharides (LPS). In future work, we will further explore related mechanisms, including cartilage degeneration, oxidative stress, and synovial disease.

The authors report no conflict of interest in this communication.

© 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.